60 results about "Gestational age" patented technology

Rapid and accurate in-vivo assessment of cerebral white matter injury particularly for pre-term infants, for timely treatment and / or prediction of outcomes has been very limited. This invention exploits the discovery that reduced high-frequency EEG intensity, particularly as shown by the upper spectral edge frequency, is a good indicator of cerebral white matter neural injury and is well correlated with MRI results. With more experience of clinical cases, a set of simple rules such as “if the spectral edge value is below 8 Hz there is a high likelihood of injury” may be validated, yet the EEG technology involved is largely invisible to the user. In the invention, EEG signals are processed by software to obtain, store, and graphically display bilaterally collected EEG spectral edge and intensity values over from hours to weeks. Rejection of corrupted signals by filtering and gating means is responsive to incoming signal characteristics, to additional inputs such as motion sensors or impedance tests, and to patient data (gestational age in particular). The invention includes the software and methods of use.

A method for determining the volume of an irregularly shaped body part or body such as a fetus using a 3D ultrasonic image composed of light and dark pixels. A caliper is placed on a portion whose volume is to be determined and a computer having the image, automatically counts every pixel with the same echogenicity in every direction as long as it is continuous with the spot the caliper is in, and wherein the computer means stops counting in any direction where the pixels become significantly more echogenic (dark). The volume of the portion, is determined, based on the counted number of pixels and the magnification of the image; and the calculated volume is used to determine physiological characteristics based on known values such as fetal gestation age.

Rapid and accurate in-vivo assessment of cerebral white matter injury particularly for pre-term infants, for timely treatment and / or prediction of outcomes has been very limited. This invention exploits the discovery that reduced high-frequency EEG intensity, particularly as shown by the upper spectral edge frequency, is a good indicator of cerebral white matter neural injury and is well correlated with MRI results. With more experience of clinical cases, a set of simple rules such as "if the spectral edge value is below 8 Hz there is a high likelihood of injury" may be validated, yet the EEG technology involved is largely invisible to the user. In the invention, EEG signals are processed by software to obtain, store, and graphically display bilaterally collected EEG spectral edge and intensity values over from hours to weeks. Rejection of corrupted signals by filtering and gating means is responsive to incoming signal characteristics, to additional inputs such as motion sensors or impedance tests, and to patient data (gestational age in particular). The invention includes the software and methods of use.

An ultrasound system includes a transducer array comprising a multiplicity of transducer elements configured to acquire image data of an object, a display system for displaying an image of the object based on the acquired image data, and an image processor module. The image processor module is programmed to calculate the curvature of the image, and identify an object feature based on the calculated curvature and based on known feature tendencies of the object.

The present invention concerns a global maternal serum proteome map and its changes during healthy gestation. Accordingly, the present invention provides an important tool for plasma-based maternal-fetal diagnostics.

The present invention relates to a system and a method of automated gestational age assessment of fetus. An ultrasound system includes a transducer array comprising a multiplicity of transducer elements configured to acquire image data of an object, a display system for displaying an image of the object based on the acquired image data, and an image processor module. The image processor module is programmed to calculate the curvature of the image, and identify an object feature based on the calculated curvature and based on known feature tendencies of the object.

PAPP-A2 is used as a marker for monitoring, predicting and diagnosing preeclampsia in pregnant women. PAPP-A2 levels in pregnant women with preeclampsia are higher than PAPP-A2 levels in normal pregnant women. This is especially true of PAPP-A2 levels that are measured later on in the pregnancy. PAPP-A2 levels may be measured early in pregnancy in order to predict the likelihood of the patient having preeclampsia. Preeclampsia may also be diagnosed at later gestational ages when the levels of PAPP-A2 are more pronounced than normal PAPP-A2 levels at the same gestational age. The present invention relates to methods of assessing, predicting and diagnosing preeclampsia as well as a kit-of-parts for assessing, predicting and diagnosing preeclampsia.

The gestational wheel calculator of the current invention greatly extends the function and usefulness of the basic gestational calculation wheel by providing increased accuracy of gestational dates by using an average cycle length adjuster, provides paternity information using a sperm exposure marker, provides more accurate ultrasound and other test measurements by using scales printed parallel to gestational age, and provide a means of accurately aligning these measurements with the proper calendar or gestational date by including a transparent marker arm. In addition, normal range and error functions are included on the marker arm. A one-fourth year window is used to increase the surface area of information available for viewing charts, tables, and promotions on the underlying base plate. Easier reading of the calculator is provided by special markers for the first day of each calendar month and by providing sub-marks for each day within a gestational week. Scheduling conflicts are improved by providing a weekday scale covering the entire nine month duration of pregnancy. The other side of the gestational wheel can be used to provide additional promotional or informational items including rotating transparent windows to display additional surface area, to provide means of calculating algorithm solutions for body mass index, and display observational data for EFW, delta OD 450, and AFI.

Methods, systems and computer program products for estimating the gestational age of a fetus are provided. According to one embodiment, the method generates a component image from a segmented ultrasound image of a fetal head. The component image includes one or more edges. The method then identifies a third ventricle within the component image. The method estimates a length of a bi-parietal diameter, based at least in part on the orientation of the third ventricle. Thereafter, the method estimates the gestational age of the fetus.

The present invention provides a method, an assay and a kit for providing an indication of abnormal cell function. It was surprisingly found that the change in the serum ADAM12 concentration in individuals was useful as a prognostic tool to predict the clinical outcome, complications and mortality following an abnormal cell function. The present inventors describes ADAM12 as a overall general marker for abnormal cell function, and the present inventor for the first time demonstrate that ADAM12 is an important indicator of fetal chromosomal disease and placenta function. Specifically ADAM12 is a good marker for e.g. Downs's syndrome, trisomy 18, preeclampsia, Turner syndrome in both first and second trimester. The present inventors developed an enzyme-linked immunosorbent assay (ELISA) and a time-resolved immunofluorometric assay for the quantification of ADAM12 in serum. The present application demonstrates in several examples the variation of the ADAM12 level in fetal abnormality and / or adverse pregnancy outcomes correlated gestational age when compared to normal controls. It is an object of the invention to provide an improvement of the existing marker tests that exhibits a decreased false positive rate.

The embodiment of the invention discloses an individual emotion adjusting system adopting music treatment facing pregnant women. The system comprises a gestational age feature identification module, avoice interaction and semantic emotion identification module, a sign physiological parameter processing module, a brain wave physiological parameter processing module and a physical therapy music recommending module. The embodiment of the invention further discloses an individual emotion adjusting method adopting music treatment facing pregnant women. Due to the adoption of the technical scheme,the negative psychological mood generated during the gestation period of the pregnant women can be effectively alleviated, the system and the method can be applied to hospital care, home nursing and the application fields under the relevant mental nursing situations. A basic model of the system is an anthropomorphic robot, by recognizing the gestational age features of the pregnant women and the relevant physiological parameters, the corresponding music is pushed for regulating the emotion of the pregnant women, and meanwhile, a physiological, psychological and music 'emotion relieving medicaltreatment report' is provided for reference.

The invention discloses a method for acquiring the concentration of fetal cell-free DNA. For the length data of cfDNA fragments in maternal peripheral blood, a Gaussian mixture model with K normal distributions is adopted to quantize maternal and fetal cfDNA, five wave crests and corresponding distribution ranges are automatically and accurately acquired, and then the concentration of fetal cfDNA is obtained. The method provides more suitable and more reliable concentration of fetal cfDNA for non-invasive prenatal testing (NIPT) and has universality and accuracy. The method is effective to both male fetuses and female fetuses as the distribution areas of lengths of maternal and fetal cfDNA fragments are dynamically determined; besides, the distribution of maternal and fetal cfDNA can be automatically acquired and recognized for samples of different fetuses of different gestational ages, and thus the accuracy of the concentration of fetal cfDNA is guaranteed.

The invention discloses a pig feed additive, as well as a gunk and a mixed batch thereof. The feed additive disclosed by the invention contains the following components in parts by weight: 5-10 parts of glycine betaine, 10-20 parts of an acidifier, 2-8 parts of algal polysaccharides, and 5-10 parts of crystal inulin. By using the feed additive disclosed by the invention to feed a pregnant sow, especially the constipation of the sow with high gestational age can be relieved; the birth number and healthy piglets can be increased; the fetiferous capacity of the sow is also increased.

Disclosed are a fetus electrocardiogram signal measuring method and its device that are capable of measuring the electrocardiogram signals of a fetus even during fetus movements and even at a gestational age during which the measurement current is weak, without the need for reattaching the electrodes and providing any shield room, even if the mother is a hospitalized or ambulant pregnant woman. The fetus electrocardiogram signal measuring device includes (1) high input impedance electrodes, (2) region-variable ground electrodes, and (3) a differential amplifier circuit and an optimization computing section.

A serum-based biomarker for diagnosing gestational diabetes, preeclampsia and fetal growth restriction (GDM-PREEC-FGR), based on retinoid profiling, and a method for diagnosing GDM-PREEC-FGR that specifically uses a blood sample to identify and measure the concentrations of retinol (vitamin A alcohol), retinyl esters and retinoic acid.

The invention provides a method for screening for and detection of diabetes mellitus in a subject that comprises assaying a test sample of urine from the subject for a metabolic marker of diabetes. An elevated or reduced amount of marker present in the test sample compared to a control sample is indicative of diabetes. The method can be used to screen for gestational diabetes early in pregnancy, or to detect diabetes or susceptibility to diabetes, in pregnant or non-pregnant subjects.

The present invention discloses a Down's syndrome risk assessment method for prenatal screening in pregnant metaphase, which includes the following steps: 1) collecting serological index testing results of pregnant women who meet the requirement of age, gestation age and weight; 2) determining gestation ages; 3) determining a median of a serological index of normal pregnant women of each of pregnancy days to obtain a regression formula of the median of the serological index of the normal pregnant women of each of pregnancy days relative to pregnancy days; 4) determining a multiple of the median of the tested pregnant women; 5) adjusting the multiple of the median of the tested pregnant women by the regression formula; 6) establishing a coefficient of a risk assessment formula of Down's syndrome by Logistic regression; 7) establishing the risk assessment formula of a triple test scheme and a double test scheme of Down's syndrome. The method based on pregnancy days and applied to prenatal screening aims at Chinese pregnant women, and has high positive rate and low false positive.

The invention discloses an SNP (Single Nucleotide Polymorphism) marker for detecting the diseasing risk of gestational diabetes mellitus. The SNP marker comprises 12 SNP sites of a personal genome, wherein the 12 SNP sites are rs7903146, rs12255372, rs 5219, rs7754840, rs4402960, rs1387153, rs10830963, rs2237892, rs1801278, rs1799884, rs1801282 and rs1063192. The SNP marker disclosed by the invention has the beneficial effects that the SNP sites selected in the invention summarize the scientific article results published at home and abroad since 1994-2016, find risk gene sites with consistentresults as detection target points, simultaneously consider the mutual action between genes and solve the problems of imperfect early screening methods and high missed-diagnosis rate for GDM on the current clinics; and after introduction of gene detection, the missed-diagnosis rate of early screening can be greatly reduced, the benefit for early intervention can be achieved and the diseasing riskof the gestational diabetes mellitus can be effectively reduced.

A method operable to more accurately monitor the state and function of the cervix is provided. Embodiments of the present invention relate generally to detection of fluorescence from the female mammalian cervix. More particularly, embodiments of the present invention relate to predicting true term and preterm labor and delivery, characterizing the function and state of the cervix, and for assessing and monitoring the efficacy of treatments for the cervix. Embodiments of the present disclosure use light induced fluorescence (LIF) via a non-invasive optical probe to accurately and quantitatively measure changes in the cervical tissue during pregnancy and labor. As gestational age increases, the LIF decreases. Ideally, cervical collagen should be at a minimum just prior to delivery. The present invention can be used to monitor the state and function of the cervix during pregnancy, as well as efficacy of cervical treatments during pregnancy.

Method and system for determining a volume of a placenta in utero. The placenta in utero may be modeled as having a convex-concave shape (e.g., like that of a portion of a spherical shell). Volume of the placenta may be determined based on the width (or height) and thickness of the placenta, or based on width, height and thickness of the placenta. Placenta size characteristics may be measured using imaging techniques, such as ultrasound. In one aspect of the invention, a volume of a placenta in utero may be compared to the volume of other placentas for similar gestational age, and a determination regarding whether the placenta volume poses a risk to fetal health may be made.

The gestational wheel calculator of the current invention greatly extends the function and usefulness of the basic gestational calculation wheel by providing increased accuracy of gestational dates by using an average cycle length adjuster, provides paternity information using a sperm exposure marker, provides more accurate ultrasound and other test measurements by using scales printed parallel to gestational age, and provide a means of accurately aligning these measurements with the proper calendar or gestational date by including a transparent marker arm. In addition, normal range and error functions are included on the marker arm. A one-fourth year window is used to increase the surface area of information available for viewing charts, tables, and promotions on the underlying base plate. Easier reading of the calculator is provided by special markers for the first day of each calendar month and by providing sub-marks for each day within a gestational week. Scheduling conflicts are improved by providing a weekday scale covering the entire nine month duration of pregnancy. The other side of the gestational wheel can be used to provide additional promotional or informational items including rotating transparent windows to display additional surface area, to provide means of calculating algorithm solutions for body mass index, and display observational data for EFW, delta OD 450, and AFI.

The invention provides a gestational age prediction method. The gestational age prediction method includes steps of setting up a gestational age estimation table of the correspondence of various physical parameters and the gestational age, and subdividing according to areas of the table and / or the pro-gestation body weight of a pregnant woman; acquiring the physical parameters of fetus; predicting the gestational age according to the physical parameters and the gestational age estimation table. The invention further provides a corresponding gestational age prediction system.

This disclosure relates to methods of predicting and diagnosing preeclampsia and eclampsia in pregnant subjects. These methods include detecting a decrease of soluble c-kit in a sample obtained from the pregnant subject. A significantly reduced concentration of soluble c-kit in the sample as compared to a gestational age-adjusted control indicates that the pregnant subject will develop or has preeclampsia or eclampsia.

A method to characterize shape variations in brain ventricles during embryonic growth in mammals, the method including extracting a brain ventricle skeleton from one or more images, calculating a volume profile for the skeleton using the extracted images, partitioning the brain ventricle based on the volume profile along the skeleton, the brain ventricle being partitioned into two lateral ventricles and a main ventricle, the main ventricle being further partitioned into three sub regions, determining volume vectors of the two lateral ventricles and the three sub regions, computing a means square error between the determined computed volume vectors and a pretrained mean volume vector of embryos during different gestational stages, and classifying the embryo to the gestational stage having the lowest mean square error. A method to characterize mutant detection in mammals, the method including acquiring one or more images, computing a volume profile directly along a path of the detected skeleton from the one or more images, aligning the volume profile against a standard profile, and evaluating the volume profile against the standard profile to detect a mutation.

The invention relates to the field of an internet technology, in particular to a recommended method for intelligent catering for pregnant women suffering from gestational diabetes based on food habits. The recommended method comprises the following steps of S1, inputting basic information of the pregnant women; S2, according to the basic information of the pregnant women, performing calculation and analysis on energy required by each day; S3, recording analysis results; S4, according to the required energy, performing energy distribution; S5, according to the energy distribution, performing meal time and the meal amount distribution; and S6, referring to a food exchange table, obtaining a catering scheme. The internet technology is adopted, and according to the living food habits of the pregnant women suffering from gestational diabetes at the gestation period, a reasonable food and drink scheme is recommended, and the blood sugar of the pregnant women can be controlled to a reasonablerange, so that the purpose of reducing complication and improving quality of born population is achieved. Under the premise that the blood sugar is controlled, corresponding foods are recommended tomeet food and drink preference of the pregnant women as far as possible, the food and drink compliance of the pregnant women can be improved, and the recommended method is suitable for being promotedwidely.

The invention discloses a method for establishing an early screening scale for risk assessment of gestational diabetes. The method comprises the following steps of consulting domestic and foreign authoritative scientific research literature, determining a susceptibility gene SNP selection standard, and finding a candidate gene site; designing a primer for nucleic acid mass spectrometric analysis on each SNP sites, and performing PCR amplification and genetic test; establishing a risk assessment model of complex diseases, and calculating heredity risk value of individuals; and combining the heredity risk valve with an external cause risk factor, and establishing the early screening scale for risk assessment of gestational diabetes. According to the method, internal and external factor conjoint analysis is adopted, and through the early screening scale for risk assessment of gestational diabetes, early screening is performed, the risk assessment accuracy is greatly increased, and the clinical diagnosis fail rate is reduced.

The invention discloses a method for correcting multiple of median of a serum marker in second-trimester prenatal screening. The method is characterized by comprising the following steps of: (1) acquiring related data, such as a serum marker detection result, weight and the like of a pregnant woman with age, gestational age and weight meeting the requirement; (2) determining the gestational age (day) based on gestational day; (3) determining the median of the serum marker of a normal pregnant woman group on each gestational day to obtain a regression formula of the median of the serum marker of the normal pregnant woman group relative to the day on each gestational day; (4) determining the multiple of the median of a detected pregnant woman; and (5) correcting the multiple of the median of the detected pregnant woman by using a weight regression formula. The method is applied to the gestational day-based prenatal screening established special for a Chinese pregnant woman group, and has the advantages of high detection ratio and low false positive.

The invention belongs to the technical field of popular science display, specifically relates to a manufacturing method for early embryo presentation model of mouse. The method comprises the steps of fetching newly born mouse with 8.5 days of gestational age, putting the mouse in 4% of PFA for 24h, preparing 200ml and 1% of agar, pouring the agar in a glass dish after being heated and melted by a microwave oven, putting the mouse specimen in the agar in semi-solidified state, cutting the specimen with the agar by the blade after the agar is completely solidified, putting the specimen into a transparent glass specimen bottle, pouring 4% of PFA in the specimen bottle for long-term storage. The embryo model is prepared by living body fixing method, agar and 4% of PFA, and then the mouse embryo in different stages can be presented vividly and completely in the manner of real specimen.